Search

Displaying results 7191 - 7200 of 10000 in total
  1. Drug

    PPI-2458

    go.drugbank.com/drugs/DB05864
    Investigational

    PPI-2458 represents a potentially new and important addition to the growing list of therapeutics aimed at specific molecular oncology targets. … PPI-2458 is a novel, proprietary molecule belonging to the fumagillin class of compounds that specifically targets the MetAP-2 enzyme.

  2. Drug

    LJP 1082

    go.drugbank.com/drugs/DB05446
    Experimental

    The target of the LJP 1082's clot-promoting antibodies is a small region on a key blood protein called beta 2-glycoprotein I. … LJP 1082 is a Toleragen that is designed to shut down the B cells that produce antibodies to ß2 GP1.

    Categories: Compounds used in a research, industrial, or household setting
  3. Drug

    TGAAC94

    go.drugbank.com/drugs/DB06175
    Investigational

    tgAAC94 is a recombinant adeno-associated virus serotype 2 (AAV2) vector containing the cDNA for a human tumor necrosis factor receptor (TNFR)-immunoglobulin (IgG1) Fc fusion (TNFR:Fc) gene. … The Health Recombinant DNA Advisory Committee (RAC) concluded that a possible role of the gene transfer in this clinical course could not definitively be excluded due to the lack of data. [A264038]

  4. Drug

    Linseed oil

    go.drugbank.com/drugs/DB11357
    Investigational

    It is an indirect additive used in food contact substances. … Linseed oil is a rich source of α-Linolenic acid extracted from the dried, ripened seeds of the flax plant *Linum usitatissimum*.

  5. Drug

    Mycobacterium w. Vaccine

    go.drugbank.com/drugs/DB15798
    Investigational

    The Mycobacterium w (M.w) vaccine is a heat-killed suspension derived from a non-pathogenic mycobacterium: mycobacterium indicus pranii. … As an immunotherapy, M.w is used against leprosy; the compound also shares antigens with M. tuberculosis.

  6. Drug

    AGS-004

    go.drugbank.com/drugs/DB05742
    Investigational

    AGS-004 is a personalized RNA-loaded dendritic cellbased immunotherapy that is designed to stimulate the patient’s immune system to target and destroy the patient’s own unique viral burden. … A personalized immunotherapy addresses these issues because it is able to capture private viral mutations, providing a matched, complete immune response for each individual HIV patient.

  7. Drug

    GFT14

    go.drugbank.com/drugs/DB05061
    Experimental

    Orally absorbed GFT14 has absolutely no structural link with current treatments for dyslipidemia (statin or fibrate based). … GFT14 is a new class of medicaction for treatment of cardiometabolic disease.

  8. Drug

    AVR118

    go.drugbank.com/drugs/DB04979
    Investigational

    AVR118 represents a new type of biopolymer chemistry that also possesses novel immunomodulator activity. … This non-toxic peptide-nucleic acid, which to date has shown no indication of human toxicity, appears to stimulate the proinflammatory responses required to combat viral infections such as AIDS and human

  9. Drug

    Pegvaliase

    go.drugbank.com/drugs/DB12839
    ApprovedInvestigational

    Pegvaliase-pqpz is a homotetrameric protein composed of recombinant phenylalanine ammonia lyase (rAvPAL) conjugated to N-hydroxysuccinimide (NHS)-methoxypolyethylene glycol (PEG). … The presence of a PEG moiety in pegvaliase-pqpz allows a reduced immune response and improved pharmacodynamic stability [A33284].

  10. Drug

    WX-UK1

    go.drugbank.com/drugs/DB05476
    Investigational

    WX-UK1 is a 3-amidinophenylalanine-based non-cytotoxic small molecule that belongs to a new class of drugs. … Independent studies show that administration of Wx-UK1 resulted in a decrease of tumor cell invasion, suggesting its efficacy as a an adjuvant antimetastatic therapy of carcinomas.